Pall Biotech has announced a new end-to-end integrated platform solution that accelerates development, reduces risk...
Pall Corporation has been recognised as a downstream innovator for the Cadence BioSMB Process system from Pall Biotech.
Each year, the Aspen Brooks team aligns with industry partners to celebrate products making the greatest contributions to the advancement of upstream and downstream bioprocessing.
Vice-president and general manager of Pall Biotech Mario Philips said: “We are honoured to be recognised by our industry colleagues for downstream innovation excellence and view this as another signal that our Cadence BioSMB platform is a game-changing product in the industry. The Cadence BioSMB platform is designed to enhance manufacturing operations and enable users to make a positive impact on global health.
“This is the second award for the Cadence BioSMB platform, and the sixth for the full Cadence continuous-enabling portfolio since it launched. Through innovation, we will work to continuously improve bioprocesses for today and the future.”
The Cadence BioSMB Process system can be operated in semi or fully continuous mode to deliver higher throughput efficiency and optimised media utilisation compared with traditional batch or other chromatographic approaches. Two flow range variants aimed at perfusion (Cadence BioSMB process 80 system) and batch (Cadence BioSMB process 350 system) bioreactor-based processes are available.
In both cases, the unique single-use eight column architecture enables highly flexible flow configurations through the single-use valve cassette.
In addition, the platform is easy to transition to from existing batch processes with no changes in media or assays and is fully scalable from process development to commercial manufacture.
The executive director of business development at Pall Biotech Peter Levison highlighted the modularity of the Cadence BioSMB Process 80 and 350 systems at the end of 2017 at the BPI East event.
In addition, Pall Biotech has announced it will be showcasing its award-winning Cadence™ portfolio of continuous technologies at INTERPHEX in booth #2815.
If you plan to be onsite at INTERPHEX and would like to meet the Pall team, please make an enquiry using the form on this page.
Pall Corporation has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China....
Recent advances in personalised regenerative medicine have been significant. However, further developments are needed to...
Pall Corporation has won a £1.5m shared grant from Innovate UK to investigate continuous manufacturing...